Application of PCSK9 inhibitors in practice: Challenges and opportunities

Tina Kaufman, Paul Duell, Jonathan Purnell, Cezary Wojcik, Sergio Fazio, Michael Shapiro

Research output: Contribution to journalReview article

13 Scopus citations


Although the discovery of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and development of therapeutic antagonists represent a major triumph of modern clinical medicine, efforts to implement PCSK9 inhibitors (PCSK9i) in patient care have been sobering. This practical guide examines the barriers and opportunities for the successful application of pharmacological inhibition of PCSK9 in clinical practice through introduction of a new model of care delivery-the PCSK9i clinic.

Original languageEnglish (US)
Pages (from-to)499-501
Number of pages3
JournalCirculation Research
Issue number5
StatePublished - Aug 1 2017


  • Angina
  • Cholesterol
  • Health
  • Insurance
  • LDL
  • Patient care
  • Secondary prevention
  • Unstable

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Application of PCSK9 inhibitors in practice: Challenges and opportunities'. Together they form a unique fingerprint.

  • Cite this